- Report
- August 2025
- 189 Pages
Global
From €3127EUR$3,545USD£2,707GBP
€3474EUR$3,939USD£3,007GBP
- Report
- August 2025
- 185 Pages
Global
From €3127EUR$3,545USD£2,707GBP
€3474EUR$3,939USD£3,007GBP
- Report
- August 2025
- 183 Pages
Global
From €3127EUR$3,545USD£2,707GBP
€3474EUR$3,939USD£3,007GBP
- Report
- August 2025
- 186 Pages
Global
From €3127EUR$3,545USD£2,707GBP
€3474EUR$3,939USD£3,007GBP
- Report
- August 2025
- 198 Pages
Global
From €3127EUR$3,545USD£2,707GBP
€3474EUR$3,939USD£3,007GBP
- Report
- August 2025
- 196 Pages
Global
From €3127EUR$3,545USD£2,707GBP
€3474EUR$3,939USD£3,007GBP
- Report
- August 2025
- 180 Pages
Global
From €3127EUR$3,545USD£2,707GBP
€3474EUR$3,939USD£3,007GBP
- Report
- November 2024
- 150 Pages
Global
From €3395EUR$3,850USD£2,939GBP
€4277EUR$4,850USD£3,703GBP
- Report
- April 2025
- 200 Pages
Global
From €3960EUR$4,490USD£3,428GBP
- Report
- March 2025
- 150 Pages
Global
From €3395EUR$3,850USD£2,939GBP
€4277EUR$4,850USD£3,703GBP
- Report
- September 2025
- 250 Pages
Global
From €3960EUR$4,490USD£3,428GBP
- Report
- February 2025
- 200 Pages
Global
From €3960EUR$4,490USD£3,428GBP
- Report
- February 2025
- 200 Pages
Global
From €3960EUR$4,490USD£3,428GBP
- Report
- January 2025
- 250 Pages
Global
From €3960EUR$4,490USD£3,428GBP
- Report
- August 2025
- 182 Pages
Global
From €3127EUR$3,545USD£2,707GBP
€3474EUR$3,939USD£3,007GBP
- Report
- August 2025
- 197 Pages
Global
From €3127EUR$3,545USD£2,707GBP
€3474EUR$3,939USD£3,007GBP
- Report
- August 2025
- 186 Pages
Global
From €3127EUR$3,545USD£2,707GBP
€3474EUR$3,939USD£3,007GBP
- Report
- August 2025
- 199 Pages
Global
From €3127EUR$3,545USD£2,707GBP
€3474EUR$3,939USD£3,007GBP
- Report
- August 2025
- 195 Pages
Global
From €3127EUR$3,545USD£2,707GBP
€3474EUR$3,939USD£3,007GBP
- Report
- August 2025
- 185 Pages
Global
From €3127EUR$3,545USD£2,707GBP
€3474EUR$3,939USD£3,007GBP

Continuous bioprocessing is a biotechnology-based approach to the production of biopharmaceuticals, such as vaccines, monoclonal antibodies, and recombinant proteins. It involves the use of continuous manufacturing techniques, such as continuous cell culture, continuous chromatography, and continuous purification, to produce biopharmaceuticals in a more efficient and cost-effective manner than traditional batch-based processes. This approach also allows for greater control over the production process, resulting in higher quality products.
Continuous bioprocessing has become increasingly popular in recent years, as it offers a number of advantages over traditional batch-based processes. These include improved process control, increased product yield, reduced production costs, and shorter production times.
Some companies in the continuous bioprocessing market include Merck KGaA, Novartis, Pfizer, Sanofi, and Lonza. Show Less Read more